Contact Us

News Room

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

5-18-23

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

5-16-23

EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments

5-3-23

EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023

4-26-23

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

4-17-23

EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

3-27-23

EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

3-20-23

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

3-2-23

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

2-27-23

EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

2-27-23

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

2-23-23

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2-16-23

EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

1-23-23

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

1-17-23

EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

1-5-23

EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

1-4-23

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12-16-22

EyePoint Pharmaceuticals Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™

11-16-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

11-16-22

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

11-7-22

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

11-2-22

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

10-26-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10-17-22

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

9-29-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

9-16-22

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

9-6-22

Load More

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. With an Eye on Patients is a trademark of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, and Delivering Innovation to the Eye are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc. Verisome is a registered trademark of Ramscor, Inc. All other trademarks are the property of their respective owners.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, DEXYCU, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

04/2021
US-EYP-2100003

Linkedin Facebook Twitter